JP2011500007A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500007A5 JP2011500007A5 JP2010528323A JP2010528323A JP2011500007A5 JP 2011500007 A5 JP2011500007 A5 JP 2011500007A5 JP 2010528323 A JP2010528323 A JP 2010528323A JP 2010528323 A JP2010528323 A JP 2010528323A JP 2011500007 A5 JP2011500007 A5 JP 2011500007A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- seq
- app
- mutation
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035772 mutation Effects 0.000 claims 26
- 239000012634 fragment Substances 0.000 claims 23
- 241001465754 Metazoa Species 0.000 claims 16
- 108020004705 Codon Proteins 0.000 claims 13
- 239000000126 substance Substances 0.000 claims 12
- 102000001708 Protein Isoforms Human genes 0.000 claims 11
- 108010029485 Protein Isoforms Proteins 0.000 claims 11
- 102220006209 rs193922916 Human genes 0.000 claims 11
- 210000000056 organ Anatomy 0.000 claims 10
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 claims 9
- 102000046783 human APP Human genes 0.000 claims 9
- 230000002159 abnormal effect Effects 0.000 claims 8
- 230000008021 deposition Effects 0.000 claims 8
- 230000009261 transgenic effect Effects 0.000 claims 8
- 230000007170 pathology Effects 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 238000003745 diagnosis Methods 0.000 claims 5
- 108020004999 messenger RNA Proteins 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 238000012216 screening Methods 0.000 claims 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000002068 genetic effect Effects 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 102000001049 Amyloid Human genes 0.000 claims 3
- 108010094108 Amyloid Proteins 0.000 claims 3
- 102000054727 Serum Amyloid A Human genes 0.000 claims 3
- 108700028909 Serum Amyloid A Proteins 0.000 claims 3
- 238000002659 cell therapy Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 230000001575 pathological effect Effects 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 241000252212 Danio rerio Species 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 102100040243 Microtubule-associated protein tau Human genes 0.000 claims 2
- 102000012412 Presenilin-1 Human genes 0.000 claims 2
- 108010036933 Presenilin-1 Proteins 0.000 claims 2
- 102000012419 Presenilin-2 Human genes 0.000 claims 2
- 108010036908 Presenilin-2 Proteins 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 241000255601 Drosophila melanogaster Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 101100268553 Homo sapiens APP gene Proteins 0.000 claims 1
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims 1
- 241001599018 Melanogaster Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 101150031224 app gene Proteins 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 239000012620 biological material Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 125000003636 chemical group Chemical group 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 238000005520 cutting process Methods 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 238000010827 pathological analysis Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 210000001082 somatic cell Anatomy 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 108010026424 tau Proteins Proteins 0.000 claims 1
- 229940104230 thymidine Drugs 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001975A ITMI20071975A1 (it) | 2007-10-12 | 2007-10-12 | Prodotti e loro uso per la diagnosi prevenzione e-o cura di patologie umane e-o animali caraterizzate dalla anomala deposizione di sostanza b-amiloide e-o similamiloide in organi e tesstui umani e-o animali e metodo di screening per la determinazione |
| PCT/EP2008/008595 WO2009047002A2 (en) | 2007-10-12 | 2008-10-10 | Products and their use for the diagnosis, prevention, and/or care of human and/or animal pathologies characterised by the anomalous deposition of b-amyloid and/or amyloid-like substance in human and/or animal organs and tissues, and screening method for determining the risk of such pathologies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011500007A JP2011500007A (ja) | 2011-01-06 |
| JP2011500007A5 true JP2011500007A5 (enExample) | 2011-05-12 |
Family
ID=40313814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528323A Pending JP2011500007A (ja) | 2007-10-12 | 2008-10-10 | βアミロイドおよび／またはアミロイド状物質のヒトおよび／または動物の臓器および組織への異常堆積を特徴とするヒトおよび／または動物の病理の診断、予防、および／または、処置のための製品およびその利用法、および、病理の危険性を判定するスクリーニング方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110010785A1 (enExample) |
| EP (1) | EP2220251B1 (enExample) |
| JP (1) | JP2011500007A (enExample) |
| CN (1) | CN102037136A (enExample) |
| ES (1) | ES2607897T3 (enExample) |
| IT (1) | ITMI20071975A1 (enExample) |
| WO (1) | WO2009047002A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010001198A1 (de) * | 2010-01-26 | 2011-07-28 | Robert Bosch GmbH, 70469 | Verfahren zur Identifikation von Verbrauchern bzw. Erzeugern in einem pneumatischen, hydraulischen oder elektrischen Netz |
| US9238796B2 (en) | 2010-06-04 | 2016-01-19 | Toagosei Co. Ltd. | Cell growth-promoting peptide and use thereof |
| JP5650249B2 (ja) * | 2011-01-07 | 2015-01-07 | セイコーエプソン株式会社 | アミロイド前駆体タンパク質のシグナルペプチドに対する抗体 |
| WO2013180011A1 (ja) | 2012-05-28 | 2013-12-05 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| WO2014061749A1 (ja) | 2012-10-18 | 2014-04-24 | 東亞合成株式会社 | ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用 |
| CN102943126A (zh) * | 2012-12-12 | 2013-02-27 | 芮屈生物技术（上海）有限公司 | 老年性痴呆病变前期APP基因mRNA水平原位杂交筛查试剂盒及筛查方法和应用 |
| DE102013201324B4 (de) | 2013-01-28 | 2024-05-16 | Aktiebolaget Skf | Verfahren zum Bestimmen einer Lagervorspannung |
| CN106574930B (zh) * | 2014-05-22 | 2019-09-03 | 株式会社岛津制作所 | 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法 |
| US20160011616A1 (en) * | 2014-07-11 | 2016-01-14 | Microsoft Technology Licensing, Llc | Power management |
| WO2016172955A1 (zh) * | 2015-04-30 | 2016-11-03 | 江苏挪贝肽医药科技有限公司 | 一种筛选用于治疗阿尔茨海默病的药物和治疗靶点的方法 |
| CN109776665B (zh) * | 2019-02-02 | 2021-02-05 | 首都医科大学宣武医院 | 阿尔茨海默病新突变、其稳转细胞模型及医药用途 |
| IT201900010722A1 (it) * | 2019-07-02 | 2021-01-02 | Fondazione Irccs St Neurologico Carlo Besta | Composto e composizione per il trattamento multi-obiettivo di disturbi legati alla proteina tau |
| EP4262846A4 (en) * | 2020-12-18 | 2024-11-20 | Baylor College of Medicine | ADMINISTRATION OF ABETA VARIANTS FOR INHIBITION OF AGGREGATION |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7196163B2 (en) * | 2001-05-22 | 2007-03-27 | Merk & Co., Inc. | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity |
| US20050106731A1 (en) * | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| BRPI0610093A2 (pt) * | 2005-05-05 | 2008-12-09 | Merck & Co Inc | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente |
| MX2008006957A (es) * | 2005-11-30 | 2008-10-20 | Abbott Lab | Metodos para la preparacion de formas recombinantes de proteina beta-amiloide humana y usos de estas proteinas. |
-
2007
- 2007-10-12 IT IT001975A patent/ITMI20071975A1/it unknown
-
2008
- 2008-10-10 CN CN2008801213173A patent/CN102037136A/zh active Pending
- 2008-10-10 WO PCT/EP2008/008595 patent/WO2009047002A2/en not_active Ceased
- 2008-10-10 EP EP08838209.8A patent/EP2220251B1/en active Active
- 2008-10-10 US US12/682,578 patent/US20110010785A1/en not_active Abandoned
- 2008-10-10 ES ES08838209.8T patent/ES2607897T3/es active Active
- 2008-10-10 JP JP2010528323A patent/JP2011500007A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500007A5 (enExample) | ||
| KR102461511B1 (ko) | 인간화된 c5 및 c3 동물 | |
| EP2220251B1 (en) | Method for the diagnosis of pathologies characterised by the anomalous deposition of amyloid in organs and tissues by detecting a mutation at position 673 in app770, and vector and peptide for use in the therapy of said pathologies | |
| Semenova et al. | An engineered 800 kilobase deletion of Uchl3 and Lmo7 on mouse chromosome 14 causes defects in viability, postnatal growth and degeneration of muscle and retina | |
| US20110107445A1 (en) | Efficient Insertion of DNA Into Embryonic Stem Cells | |
| WO2008072540A1 (ja) | Ｔｏｌ１因子のトランスポザーゼ及びそれを用いたＤＮＡ導入システム | |
| US5858973A (en) | Transcription factor and uses therefor | |
| AU5595900A (en) | Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation | |
| KR20190122231A (ko) | 신장 및 간 장애의 인간화 모델 | |
| JP2021169461A (ja) | 寿命に関する動物モデル並びに寿命を延ばす及び腫瘍化を阻害する関連方法 | |
| US8399257B2 (en) | Transposition of maize Ac/Ds elements in vertebrates | |
| EP1324652B1 (en) | Transgenic drosophila melanogaster expressing beta amyloid | |
| Matsuyama et al. | Identification and characterization of the miniature pig Huntington's disease gene homolog: evidence for conservation and polymorphism in the CAG triplet repeat | |
| US6475723B2 (en) | Pathogenic tau mutations | |
| EP2400023B1 (en) | A non-human animal model for amyotrophic lateral sclerosis (ALS) with loss-of-TDP-43 function | |
| CN112292030A (zh) | 进行性骨化性纤维发育不良的啮齿类动物模型 | |
| EP3585163B1 (en) | Non-human animals comprising slc30a8 mutation and methods of use | |
| Lahiri et al. | Nephropathy and defective spermatogenesis in mice transgenic for a single isoform of the Wilms' tumour suppressor protein, WT1− KTS, together with one disrupted Wt1 Allele | |
| US6410226B1 (en) | Mammalian and human REC2 | |
| CN117230077B (zh) | Hakai基因在RP疾病模型构建中的应用及构建方法 | |
| JP5240756B2 (ja) | 軟骨疾患のモデル非ヒト動物 | |
| JPWO2004108920A1 (ja) | 抗肥満薬のスクリーニング方法及び肥満モデル動物 | |
| US20200109422A1 (en) | Methods of full gene replacement and transgenic non-human cells comprising full human genes | |
| EP1208200A2 (en) | Transgenic animal model for neurodegenerative diseases | |
| HK40017998B (en) | Non-human animals comprising slc30a8 mutation and methods of use |